Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFT505 in Impaired Glucose Tolerance and Abdominal Obesity
NCT01275469Phase 2Completed
- Sponsor
- Genfit
- Start
- Jun 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elafibranor in impaired glucose tolerance (IGT), abdominal obesity, sponsored by Genfit. Started Jun 2009; status: completed.
02
Drugs
elafibranor
03
Conditions
impaired glucose tolerance (IGT)abdominal obesity
Beyond the preview
Go deeper on NCT01275469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275469.